Los Angeles Capital Management LLC Has $3.83 Million Stock Position in Alkermes plc (NASDAQ:ALKS)

Los Angeles Capital Management LLC lessened its stake in Alkermes plc (NASDAQ:ALKS) by 0.4% in the third quarter, Holdings Channel reports. The firm owned 136,697 shares of the company’s stock after selling 605 shares during the quarter. Los Angeles Capital Management LLC’s holdings in Alkermes were worth $3,826,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of the company. Price T Rowe Associates Inc. MD raised its position in shares of Alkermes by 421.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 8,326,256 shares of the company’s stock valued at $225,393,000 after buying an additional 6,730,671 shares in the last quarter. Pacer Advisors Inc. increased its stake in Alkermes by 31.8% in the second quarter. Pacer Advisors Inc. now owns 5,640,642 shares of the company’s stock valued at $135,939,000 after acquiring an additional 1,362,079 shares during the last quarter. Dimensional Fund Advisors LP raised its position in Alkermes by 14.8% during the second quarter. Dimensional Fund Advisors LP now owns 2,884,012 shares of the company’s stock valued at $69,507,000 after purchasing an additional 371,039 shares in the last quarter. Armistice Capital LLC lifted its stake in Alkermes by 301.5% during the second quarter. Armistice Capital LLC now owns 2,699,179 shares of the company’s stock worth $65,050,000 after purchasing an additional 2,026,961 shares during the last quarter. Finally, American Century Companies Inc. boosted its holdings in shares of Alkermes by 87.1% in the 2nd quarter. American Century Companies Inc. now owns 2,203,456 shares of the company’s stock valued at $53,103,000 after purchasing an additional 1,025,905 shares in the last quarter. Institutional investors own 95.21% of the company’s stock.

Wall Street Analyst Weigh In

ALKS has been the subject of several research analyst reports. The Goldman Sachs Group lowered their target price on Alkermes from $32.00 to $30.00 and set a “buy” rating for the company in a research note on Friday, October 25th. StockNews.com upgraded shares of Alkermes from a “hold” rating to a “buy” rating in a research report on Sunday, July 28th. Cantor Fitzgerald lowered their price target on shares of Alkermes from $48.00 to $43.00 and set an “overweight” rating for the company in a report on Friday, October 25th. JPMorgan Chase & Co. cut their price objective on Alkermes from $32.00 to $26.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. Finally, Stifel Nicolaus raised Alkermes from a “hold” rating to a “buy” rating and upped their target price for the stock from $25.00 to $36.00 in a report on Tuesday, November 5th. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $35.00.

Alkermes Stock Down 2.8 %

Shares of NASDAQ ALKS opened at $29.23 on Wednesday. The company has a debt-to-equity ratio of 0.22, a current ratio of 3.45 and a quick ratio of 3.03. The stock has a market capitalization of $4.73 billion, a PE ratio of 14.99, a P/E/G ratio of 0.96 and a beta of 0.47. Alkermes plc has a one year low of $22.06 and a one year high of $32.88. The business’s fifty day moving average price is $27.69 and its 200-day moving average price is $26.13.

Insiders Place Their Bets

In other news, EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total value of $309,208.63. Following the sale, the executive vice president now owns 99,238 shares of the company’s stock, valued at $2,930,498.14. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other news, EVP Craig C. Hopkinson sold 58,996 shares of the stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $30.08, for a total value of $1,774,599.68. Following the sale, the executive vice president now directly owns 83,300 shares of the company’s stock, valued at approximately $2,505,664. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Craig C. Hopkinson sold 10,471 shares of the business’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $29.53, for a total transaction of $309,208.63. Following the transaction, the executive vice president now directly owns 99,238 shares of the company’s stock, valued at approximately $2,930,498.14. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Company insiders own 4.89% of the company’s stock.

Alkermes Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.